CAS: 53-06-5; Cortisone

上下游产品

CAS号50-04-4 醋酸可的松 | CAS号3597-44-2 Androst-4-ene-1... | CAS号3941-62-6 Methyl 17α-Hydr... | CAS号128802-52-8 (3R,3aS,9aS,9bS... | CAS号382-45-6 肾上腺甾酮 | CAS号3615-87-0 4-pregnene-17 a... | CAS号3597-46-4 (+)-3,11-dioxoa... | CAS号53-36-1 甲基泼尼松龙醋酸酯 | CAS号50-23-7 氢化可的松 | CAS号516-15-4 4-孕烯-3,11,20-三酮 | CAS号72-23-1 11-去氢皮质甾酮 | CAS号1882-82-2 17Alpha-羟基孕甾-4-... | CAS号83-43-2 甲基泼尼松龙 | CAS号739-27-5 11-酮本胆烷醇酮

氢化可的松置于cerium(Iii) Bromide,双氧水体系中,用 1,4-二氧六环,水 作为反应溶剂,以64%的收率获得产物可的松
参考文献:用 H2O2 重新研究 Febr3 催化的酒精氧化:是高价铁物种 (His) 还是活性溴化物 (Rbs) 负责酒精氧化
标题:用 H2O2 重新研究 Febr3 催化的酒精氧化:是高价铁物种 (His) 还是活性溴化物 (Rbs) 负责酒精氧化
摘要:2003 年,Martı́n 等人.报道了用 Febr 3 (Cat.)/H2O 2进行绿色醇氧化,并提出了一种负责醇氧化的高价铁物质 (His).重新研究这种 Febr 3 (Cat.)/H2O 2方法使我们提出了一种不同的机制,该机制涉及用于醇氧化的反应性溴化物质 (Rbs).支持这种基于 Rbs 的机制的证据包括 (1) 我们最近从相关的 Febr 2 /H2O 2或 Cebr 3 /H2O 2原位反应生成的 Rbs 的发现系统,(2)我们一系列受控实验的结果,以及(3)一些相关的基于 Rbs 的先例(nbs,Nba 或 Br 2)显示出与伯醇相似的仲醇的高氧化选择性.这些研究使我们能够发现来自 Cebr 3 /H2O 2的 Rbs对于仲醇和苄醇的氧化效率更高,这代表了一种将醇选择性氧化为羰基的新绿色方案.
DOI:10.1021/acs.Orglett.2C01133

专利信息

专利号:US-7230101-B1
优先权日:2002-08-28
标 题:Synthesis of methotrexate-containing heterodimeric molecules
发明人：MURTHI KRISHNA K; SMITH CHASE C
权利人:GPC BIOTECH INC
摘要:The present invention relates to novel compositions of methotrexate-containing heterodimeric probe molecules, also known as chemical inducers of dimerization (CID), useful in three-hybrid assays. The invention further relates to synthesis of said compositions and their intermediates. Another aspect of the invention is a method for using the heterodimeric probe molecules described herein in drug screens to identify potential protein targets to a given ligand, optimize protein-ligand interactions, or identify potential ligands for a given protein target. In certain embodiments, the invention contemplates the synthesis of the following methotrexate-containing heterodimeric probe:

专利号:US-12383499-B2
优先权日:2018-01-01
标题:Scale up synthesis of silicasome nanocarriers
发明人：NEL ANDRE E; MENG HUAN; LIU XIANGSHENG
权利人:UNIV CALIFORNIA
摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

专利号:US-7435816-B2
优先权日:2003-04-30
标 题 :Synthesis of solanum glycosides
发明人：SHAHID MOHAMMED
权利人:SHAHID MOHAMMED
摘要:The present invention relates to the chemical synthesis of solanum glycosides, in particular to the synthesis of solasonine as well as to novel β-monosaccharide intermediate compounds, of Formula (2), where R 1 is a benzylidene, 4-nitrobenzylidene or 4-methoxybenzylidine group, and each R 2 independently is a benzoyl, acetyl or pivaloyl group:

专利号:EP-1421100-B1
优先权日:2001-08-21
标 题 :Chemical synthesis of solamargine
发明人：SHAHID MOHAMMED
权利人:GLYCOMED SCIENCES LTD
摘要:The present invention relates to the chemical synthesis of solanum glycosides, in particular to the synthesis of solamargine as well as to novel beta-monosaccharide Intermediate compounds.

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.